



Company	Ticker	Sector	Industry
GSK plc Sponsored ADR	GSK-US	Health Care	Pharmaceuticals

Business Description

GSK Plc is a healthcare company, which engages in the research, development, and manufacture of pharmaceutical medicines, vaccines, and consumer healthcare products. It operates through the following segments: Pharmaceuticals; Pharmaceuticals R&D; Vaccines and Consumer Healthcare. The Pharmaceuticals segment focuses on developing medicines in respiratory and infectious diseases, oncology, and immuno-inflammation. The Pharmaceuticals R&D segment focuses on science related to the immune system, the use of human genetics and advanced technologies, and is driven by the multiplier effect of Science x Technology x Culture. The Vaccines segment produces pediatric and adult vaccines to prevent a range of infectious diseases including, hepatitis A and B, diphtheria, tetanus and whooping cough, measles, mumps and rubella, polio, typhoid, influenza, and bacterial meningitis. The Consumer Healthcare segment develops and markets brands in the oral health, pain relief, respiratory, nutrition and gastro intestinal, and skin health categories. The company was founded in 1715 and is headquartered in Middlesex, the United Kingdom.

Price Chart

Key Info & Metrics



Empirical Research Rank:	@NA
Date Purchased:	07/19/2022
Price:	\$36.17
52-Week Range:	\$28.66 - \$58.56
Dividend Yield:	5.12%
Market Cap (\$M):	\$73,057
Forward Price-to-Earnings:	10

Total Return

Year-to-Date:	2.9%
1 Year:	-17.6%
3 Year:	-6.3%
5 Year:	26.6%

Investment Case - Updated: November 7, 2022

GlaxoSmithKline underwent a significant, company restructuring in 2022, splitting off its consumer health business, now trading as Haleon (HLN). Now, GlaxoSmithKline's revenues are generated from three, remaining sub-segments: specialty medicines (41 percent), general medicines (35 percent), and vaccines (24 percent). The pharmaceutical business is in the middle of a revival. New oncology, immuno-inflammation, and HIV drugs are offsetting declines in older off-patent respiratory and HIV drugs. The company also aims to increase the productivity of research and development spending to peer levels. The vaccine business is GlaxoSmithKline's crowned jewel. Seven of eight vaccines are over 90 percent effective. Shingrix, a shingles vaccine, revenue is expected to double to £4 billion by 2026. The company also has access to novel vaccine technologies, including mRNA, through internal research and external partnerships. The recent acquisition of Affinivax brings a next generation vaccine technology and vaccine candidates to its portfolio. Demand for GlaxoSmithKline's vaccines should grow with renewed, post-pandemic awareness of immunization in preventing severe diseases.

Disclaimer

CapFinancial Partners, LLC (dba "CAPTRUST") is a registered investment adviser. This report contains analysis/opinions as of the date of the report (subject to change without notice). This is not a recommendation to invest in an individual stock, but rather it is a summary of select data/statistics considered by CAPTRUST in making discretionary investment decisions (and may not include all relevant factors). Investing involves risk, so there is always a possibility of loss. Past performance is not a guarantee of future results. CAPTRUST (and/or associated persons) may engage in securities transactions in a manner inconsistent with the information contained herein.